Håndtering af hjertekomplikationer sekundært til medicinsk kræftbehandling
Research output: Contribution to journal › Journal article › Research › peer-review
As the prognoses of both heart and cancer patients have improved along with a longer life expectancy in the general population, the prevalence of both heart- and cancer diseases is increasing. Thus, a larger proportion of cancer patients will have cardiovascular co-morbidity and an increased risk of cardiovascular complications during and after cancer treatment. In this article, the current knowledge on the prevention, monitoring and treatment of cardiotoxicity induced by medical anti-cancer treatment with focus on anthracyclines, trastuzumab and 5-fluorouracil is described.
Translated title of the contribution | Management of cardiovascular complications secondary to medical treatment of cancer |
---|---|
Original language | Danish |
Article number | V04170269 |
Journal | Ugeskrift for Laeger |
Volume | 180 |
Issue number | 7 |
Number of pages | 5 |
ISSN | 0041-5782 |
Publication status | Published - 2018 |
Links
ID: 218615468